The European Medicines Agency is seeking feedback on draft guidance that aims to provide “actionable and focused recommendations” for assessing and improving the quality of real-world data (RWD) for regulatory use.
EMA Homes In On How To Improve RWD Quality
Draft guidance from the European Medicines Agency explores how data quality can impact the use of real-world data to generate real-world evidence for regulatory assessments.
